ARDX (Ardelyx) Other Current Liabilities: $9.4 Mil (As of Mar. 2026)


ARDX Ardelyx Inc ARDX
71 GF Score
Price $5.27
GF Value $10.22
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Other Current Liabilities?

Ardelyx ARDX +1.93% 71 Other Current Liabilities is $9.4 Mil as of Mar. 2026. GuruFocus rates ARDX with a GF Score™ of 71/100 and a GF Value™ of $10.22 (Possible Value Trap). The stock has 6 warning signs investors should review.

Ardelyx's other current liabilities for the quarter that ended in Mar. 2026 was $9.4 Mil.

Ardelyx's quarterly other current liabilities increased from Sep. 2025 ($15.1 Mil) to Dec. 2025 ($26.5 Mil) but then declined from Dec. 2025 ($26.5 Mil) to Mar. 2026 ($9.4 Mil).

Ardelyx's annual other current liabilities increased from Dec. 2023 ($17.5 Mil) to Dec. 2024 ($21.5 Mil) and increased from Dec. 2024 ($21.5 Mil) to Dec. 2025 ($26.5 Mil).

Ardelyx Other Current Liabilities Related Terms

Ardelyx Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Ardelyx's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Other Current Liabilities Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.59 10.09 17.48 21.48 26.46

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.17 11.81 15.06 26.46 9.38
ARDX
71GF Score
Ardelyx Inc ARDX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $9.4 Mil mean?
Ardelyx (ARDX) has a Other Current Liabilities of $9.4 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ardelyx.
Is Ardelyx's Other Current Liabilities too high?
Ardelyx's current Other Current Liabilities is $9.4 Mil. Overall, Ardelyx has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Other Current Liabilities compare to AVLN and INBX?
Ardelyx's Other Current Liabilities of $9.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ardelyx. Ardelyx's current Other Current Liabilities is $9.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $10.22, compared to a current price of $5.27 — trading 48.4% below its estimated fair value. The current Other Current Liabilities is $9.4 Mil. Ardelyx's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ardelyx (ARDX), the current Other Current Liabilities is $9.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of $5.27 is trading 48.4% below its estimated GF Value™ of $10.22. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for ARDX:

  • Other Current Liabilities: $9.4 Mil
  • GF Value™: $10.22 vs. price of $5.27 (48.4% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:Mexico41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
71GF Score

Get the complete analysis for ARDX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$10.22
GF Value